Timothy Chan, MD, PhD
Director, Center for Immunotherapy & Precision Immuno-Oncology
Lerner Research Institute,
9500 Euclid Avenue, Cleveland, Ohio 44195
Timothy Chan, MD, PhD, a renowned immuno-oncology and cancer genomics expert, leads the Center for Immunotherapy and Precision Immuno-Oncology, which brings together multidisciplinary experts from across the Cleveland Clinic enterprise to advance research and treatment related to the rapidly growing field of immuno-oncology.
Dr. Chan also collaborates with experts in the Center for Global and Emerging Pathogens Research, which is focused on broadening understanding of immunology and microbial pathogenesis with the goal of improving treatment for a variety of diseases, including virus-induced cancers.
He is an internationally recognized expert in precision immuno-oncology and a pioneer in using genomics to determine which patients will respond best to certain types of immunotherapies. He has published over 200 articles in peer-reviewed journals, made landmark discoveries in his field and received numerous awards, including the National Cancer Institute Outstanding Investigator Award in 2018.
Dr. Chan earned his MD and PhD in genetics from Johns Hopkins University, where he also completed a residency in radiation oncology and a postdoctoral fellowship in the division of tumor biology. He is board certified in radiation oncology and is an elected member of the Association of American Physicians.
The focus of the Chan laboratory is to understand the genomic basis of tumor development and treatment response. We use both large-scale genomic analyses and functional dissection to determine what drives oncogenesis. From this information, we seek to develop improved diagnostic and therapeutic modalities for human cancers.
- Immuno-Oncology Faculty (All Levels)
- Program Head/Faculty,Cell Therapy Developmental Therapeutics
- Faculty,Translational Regenerative Therapies for Neurologic Disorders
- Senior Research Technologist, Chan Lab
Highlighted Publications from the Chan Lab
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA*. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866. PMID: 22343889.
Rizvi N, Hellmann MD, Snyder A, Kvistborg P, Makarov M, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, and Chan TA. Cancer Immunology. Mutational landscape determines sensitivity to programmed cell death-1 blockade in non-small cell lung cancer. Science 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 1. PMID: 25765070. PMCID: PMC4993154.
Riaz N, Havel JJ, Kendall SM, Makarov V, Walsh L, Desrichard A, Weinhold N, Chan TA. Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy. Nature Genetics 2017 Feb 1;3(2):244-255. doi: 10.1001/jamaoncol.2016.1790. PMID: 27668655.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TA, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli E, Liu C, Harbison CT, Wang L, Ribas A, Wolchok, JD, and Chan TA*. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine 2014 Dec 4;371(23):2189-2199. PMID: 25409260.
Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi S, Martin-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu W, Gajweski TF, Slingluff CL, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, and Chan TA. Tumor and Microenvironment Evolution During Immunotherapy with Nivolumab. Cell 2017 Nov 2;171(4):934-949.e16. PMID: 29033130. *Corresponding author.
Gong Y, Zack TI, Morris LGT, Lin K, Hukkelhoven E, Raheja R, Veeriah S, Meng S, Viale A, Schumacher SE, Beroukhim R, and Chan TA*. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genetics 2014 Jun;46(6):588-94. doi: 10.1038/ng.2981. Epub 2014 May 4. *Corresponding author. PMID: 24793136. PMCID: PMC4251771. (featured in News and Views)
Turcan S, Makarov V, Taranda J, Fabius AWM, Wu W, Zheng Y, El-Amine N, Haddock S, Wang Y, Nanjangud G, LeKaye HC, Brennan C, Cross J, Huse JT, Kelleher NL, Osten P, Thompson CB, and Chan TA*. Mutant IDH1-Dependent Chromatin State Reprogramming, Reversibility, and Persistence. Nature Genetics 2018 Jan;50(1):62-72. PMID: 29180699.
Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein R, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA. Patient HLA class 1 genotype influences cancer response to checkpoint blockade immunotherapy. Science 2018 Feb 2;359(6375):582-587; PMID: 29217585.
Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris L.G.T., Landa I, Albornoz P, Riaz N, Nikiforov YE, Patel K, Umbricht C, Zeiger M, Kebebew E, Sherman E, Ghossein R, Fagin JA, and Chan TA. Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes. Cancer Cell 2018 Aug 13;34(2):256-270.e5. PMID: 30107176.. *Corresponding author.
Morris LGT, Kaufman AM, Gong Y, Ramaswami R, Walsh LA, Turcan S, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, Singh B, Ganly G, Liau L, Cloughesy TC, Mischel PS, Mellinghoff IM, Chan TA*. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics 2013 Mar;45(3):253-61. PMID: 23354438. PMCID: PMC3729040.
Samstein RM, Lee CH Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron D, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan C, Tabar V, Mellinghoff IK, DeAngelis LA, Ariyan CE, Lee N, Tap WD, Gounder MM, D’Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB*, Chan TA*, Morris LGT*. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14. PMID: 30643254. PMCID: PMC6365097. *Corresponding authors.
Mandal R, Samstein RM, Lee KW, Havel JJ, Wang H, Krishna C, Sabio EY, Makarov V, Kuo F, Blecua P, Ramaswamy AT, Durham JN, Bartlett B, Ma X, Srivastava RM, Middha S, Zehir A, Hechtman JF, Morris LGT, Weinhold N, Riaz N, Le DT, Diaz LA, and Chan TA. Genetic Diversity of Tumors with Mismatch Repair Deficiency Influences PD-1 Immunotherapy Response. Science 2019 May 3;364(6439):485-491. doi: 10.1126/science.aau0447. PMID: 31048490. PMCID: PMC6685207.
Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, Morris LGT, Riaz N, Lenz TL, and Chan TA. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nature Medicine 2019 Nov;25(11):1715-1720. PMID: 31700181.
Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Srivastava RM, Purohit TA, Chung J, Hoen DR, Mandal R, Setton J, Wu W, Shah R, Qeriqi B, Chang Q, Kensall S, Braunstein L, Weigelt B, Blecua P, Morris LGT, Mandelker DL, Reis-Filho JS, de Stanchina E, Powell SN, Chan TA*, Riaz N.* Mutations in homologous recombination genes BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer 2020. http://doi.org/10.1038/s43018-020-00139-8. *Co-corresponding authors.
Zhang X, Sabio E, Krishna C, Ma X, Wang J, Jiang H, Havel JJ, Chan TA. Qa-1a modulates resistance to anti-PD-1 therapy in antigen processing defective tumors. Molecular Cancer Research 2021. PMID: 33674442.
Ho AS, Kannan K, Roy DM, Morris LGT, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng, Stephanie, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, Drobnjak M, Leversha MA, Rice CE, Singh B, Iyer NG, Leemans CR, Bloemena E, Ferris RL, Seethala RR, Gross BE, Liang Y, Sinha R, Peng L, Raphael BJ, Turcan S, Gong Y, Schultz N, Kim S, Chiosea S, Shah JP, Sander C, Lee W, and Chan TA*. The Mutational Landscape of Adenoid Cystic Carcinoma. Nature Genetics 2013 Jul;45(7):791-8. PMID: 23685749.
Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA*. Somatic mutations of the Parkinson’s disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics 2010 Jan;42(1):77-82. PMID: 19946270.
Cleveland Clinic has been named as one of four institutions of a new consortium grant from the Aligning Science Across Parkinson’s (ASAP) initiative to investigate the association between Parkinson’s disease and immunity. The multi-site consortium will be led by researchers at Massachusetts General Hospital / Harvard Medical School and also includes those from the University of Houston and MD Anderson Cancer Center at the University of Texas.
VIDEO: New Center for Immunotherapy and Precision Immuno-Oncology to Help Advance Head and Neck Cancer Research
With one of the largest cell production facilities in the state and a robust biorepository, Cleveland Clinic aims to lead the future of head and neck cancer and cancer therapies, including immunotherapies. Cleveland Clinic has made a strong commitment—over $80 million—to fund its new Center for Immunotherapy and Precision Immuno-Oncology (CITI), which will support immunotherapy research and care related to many types of cancers. Hear from Brian Burkey, MD, vice chair of the Head & Neck Institute, and Timothy Chan, MD, PhD, director of CITI, about how the two teams will work together to advance head and neck cancer translational research, with the ultimate goal to enhance patient care and outcomes.